Newron Pharmaceuticals S.p.A. header image

Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2026-11-06)
CHF 8.83+0.91%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

star star star star star
4.50 4 votes No rating yet
NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A., established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company aims to expand its product portfolio through both internal research and development and strategic licensing and acquisition of novel compounds targeting the central nervous system (CNS) at various stages of development. Newron's shares are publicly traded on the SIX Swiss Exchange under the ticker symbol NWRN, as well as on the primary market of the Düsseldorf Stock Exchange and XETRA under the trading symbol NP5.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-38.6%1Y
74.5%3Y
329%5Y

Performance

61.2%1Y
66.7%3Y
75.1%5Y

Volatility

Market cap

215 M

Market cap (USD)

Daily traded volume (Shares)

34,239

Daily traded volume (Shares)

1 day high/low

8.99 / 8.39

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

4 votes
Performance:
starstarstarstarstar
3.25
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.50
Nature:
starstarstarstarstar
3.75
Uwe K.
Switzerland, 30 Mar 2025
star star star star star
Könnte interessant sein.
Caterina F
Switzerland, 26 Mar 2025
star star star star star
Worth paying attention to
Markus Fässler
Switzerland, 05 Feb 2024
star star star star star
Evenamide, Newron’s innovative drug to treat schizophrenia, has proven safe and effective in use for TRS patients.

EQUITIES OF THE SAME SECTOR

Jubilant Pharmova Limited
Jubilant Pharmova Limited Jubilant Pharmova Limited Valor: 2477953
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.88%INR 938.60
Orion Oyj
Orion Oyj Orion Oyj Valor: 2553360
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 101.00
Beiersdorf AG
Beiersdorf AG Beiersdorf AG Valor: 324660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.70%EUR 85.26
Bristol-Myers Squibb Co
Bristol-Myers Squibb Co Bristol-Myers Squibb Co Valor: 914188
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.57%USD 62.14
Medios AG
Medios AG Medios AG Valor: 19069483
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.53%EUR 11.34
Centene Corp
Centene Corp Centene Corp Valor: 1313733
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.97%USD 69.74
IQVIA Holdings Inc
IQVIA Holdings Inc IQVIA Holdings Inc Valor: 39103858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.62%USD 271.83
Legend Biotech Corporation
Legend Biotech Corporation Legend Biotech Corporation Valor: 54834759
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.82%USD 23.40
2invest AG
2invest AG 2invest AG Valor: 110098281
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.25%EUR 6.32
The Platform Group AG
The Platform Group AG The Platform Group AG Valor: 57796644
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-13.06%EUR 0.55